WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) reported a return to profitability in the second quarter, driven by the termination of a regional licensing deal and renewed strategic ...

Detailed price information for Arbutus Biopharma Corp (ABUS-Q) from The Globe and Mail including charting and trades.

Detailed price information for Arbutus Biopharma Corp (ABUS-Q) from The Globe and Mail including charting and trades.

Arbutus (ABUS) delivered earnings and revenue surprises of +150.00% and +496.61%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Arbutus Biopharma Corp. ABUS) on Wednesday reported second-quarter net income of $2.5 million, after reporting a loss in the ...

On July 24, 2025, the PTO Acting Director Coke Morgan Stewart discretionarily denied Amgen’s IPR2025-00601 and IPR2025-00602 challenging ...

Surveillance of hepatocellular carcinoma (HCC), via 6-monthly ultrasonography with alpha-fetoprotein testing, is currently ...

TCG Labs Soleil, which launched in 2024 in collaboration with The Column Group, is focused on building single-drug biotechs it can position for partnerships.

Earlier this week, we learned that locally owned Martella’s Pharmacy is facing a dispute with national pharmacy benefit manager Express Scripts.Dozens of concer ...

Dispatch emerges with $216M and plans for a ‘universal’ solid tumor therapy The startup is using elements of gene and cell therapy to create medicines that could be useful against an array of tough-to ...

On the rocky water’s-edge bluffs where the Arbutus menziessii ekes out its existence, the pressure to develop is intense, and growing.